Cell MedX Corp CMXC

Cell MedX Corp. (CMXC) Engages Tamarack Advisors

[Tamarack]

DENVER, CO / ACCESSWIRE / November 3, 2016 / Cell MedX Corp. (CMXC), Cell MedX Corp. ("Cell MedX" or the "Company"), a development stage company focused on the commercialization of therapeutic devices for patients living with diseases such as diabetes, today announced that it has engaged Tamarack Advisors Inc. to develop an investor communication and outreach program. With a network of hundreds of thousands of sophisticated financial professionals, Tamarack Advisors is a leader in helping emerging public companies reach targeted investor audiences.

Cell MedX Corp. is developing cutting-edge frequency specific microcurrent technologies designed to help treat chronic and acute conditions for both clinical and self-management care. Over the past several years, the Company has been working on the development of an innovative microcurrent technology called eBalance that emits electrical frequencies that are best suited to specific conditions, such as diabetes or pain management.

The underlying technology uses the principles of microcurrents to effectuate positive outcomes for individuals suffering from a wide range of conditions. In a number of clinical studies, the topical application of microcurrents has increased production of adenosine triphosphate ("ATP") - the energy stored by cells - by up to 500%. This increased cellular function is theorized to reinvigorate cells and potentially reverse damage from illness.

The Company's eBalance technology is set to undergo observational clinical trials to evaluate its safety and efficacy. Early users of the prototype devices have reported a range of positive benefits that the Company has made available on its website (www.cellmedx.com/observations). With initial funding in place to acquire devices for the trial, investors could see tangible data early next year.

The Company believes that the market for eBalance technology could be significant since it improves upon traditional microcurrent technologies by customizing frequencies. Wellness devices - like TENS units used for pain management – have sold millions of units around the world. Meanwhile, approved medical devices that have undergone clinical trials can sell for much higher price points given the potential for reimbursements from insurance companies.

Investors interested in the medical device space may want to keep an eye on Cell MedX Corp. (CMXC) as it progresses through observational clinical trials to secure approval for its eBalance technology. In particular, investors in companies like Zynex Inc. (OTCQB:ZYXI) or larger medical devices companies like Medtronic plc (NASDAQ:MDT) may want to take a closer look.

About Cell MedX Corp.

Cell MedX Corp. is an early development stage company focused on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes, by developing technologies to help manage both the illness and related complications. For more information about the Company and its technology please visit our website at: https://cellmedx.com/, for the Company's weekly newsletter, please go to https://cellmedx.com/media/newsletters/.

For further information visit: https://cellmedx.com/

Or phone: [phone]

About Tamarack Advisors Inc.

Tamarack Advisors Inc. is a leading provider of investor communication and outreach services for emerging public companies. With an extensive network of investors and in-depth marketing expertise, the company helps clients reach and cultivate a network of long-term investors and establish a reliable shareholder base.